Why Pfizer Will Find It Hard to Appease Its Activist Investor

Posted by | ISLE Brew | 0 |

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift. WSJ.com: US Business